{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T05:01:14Z","timestamp":1774501274125,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":1558,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International Supplements"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1038\/kisup.2011.30","type":"journal-article","created":{"date-parts":[[2011,8,31]],"date-time":"2011-08-31T17:37:00Z","timestamp":1314812220000},"page":"136-141","source":"Crossref","is-referenced-by-count":80,"title":["Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation"],"prefix":"10.1016","volume":"1","author":[{"given":"Adriana S.","family":"Dusso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/kisup.2011.30_bb0010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1038\/kisup.2011.30_bb0015","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1001\/archinte.167.16.1730","article-title":"Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials","volume":"167","author":"Autier","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1038\/kisup.2011.30_bb0020","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1152\/ajprenal.00336.2004","article-title":"Vitamin D","volume":"289","author":"Dusso","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/kisup.2011.30_bb0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ki.2009.175","article-title":"Renoprotective effects of vitamin D analogs","volume":"78","author":"Li","year":"2009","journal-title":"Kidney Int"},{"key":"10.1038\/kisup.2011.30_bb0030","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1053\/ajkd.2001.20740","article-title":"Role of phosphorus in the pathogenesis of secondary hyperparathyroidism","volume":"37","author":"Slatopolsky","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/kisup.2011.30_bb0035","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","article-title":"Activated injectable vitamin D and hemodialysis survival: a historical cohort study","volume":"16","author":"Teng","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/kisup.2011.30_bb0040","first-page":"CD008175","article-title":"Vitamin D compounds for people with chronic kidney disease not requiring dialysis","volume":"4","author":"Palmer","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1038\/kisup.2011.30_bb0045","first-page":"CD005633","article-title":"Vitamin D compounds for people with chronic kidney disease requiring dialysis","volume":"4","author":"Palmer","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1038\/kisup.2011.30_bb0050","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1210\/jc.2009-1773","article-title":"Update in vitamin D","volume":"95","author":"Adams","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/kisup.2011.30_bb0055","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1681\/ASN.2009030283","article-title":"25-hydroxyvitamin D levels, race, and the progression of kidney disease","volume":"20","author":"Melamed","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/kisup.2011.30_bb0060","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ki.2010.543","article-title":"Defective maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease","volume":"79","author":"Dusso","year":"2011","journal-title":"Kidney Int"},{"key":"10.1038\/kisup.2011.30_bb0065","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0092-8674(00)80655-8","article-title":"An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3","volume":"96","author":"Nykjaer","year":"1999","journal-title":"Cell"},{"key":"10.1038\/kisup.2011.30_bb0070","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2362.1998.00253.x","article-title":"Regulation of gp330\/megalin expression by vitamins A and D","volume":"28","author":"Liu","year":"1998","journal-title":"Eur J Clin Invest"},{"key":"10.1038\/kisup.2011.30_bb0075","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.ajkd.2007.04.015","article-title":"25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III)","volume":"50","author":"de Boer","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/kisup.2011.30_bb0080","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1046\/j.1523-1755.2003.00114.x","article-title":"Gene expression of vitamin D hydroxylase and megalin in the remnant kidney of nephrectomized rats","volume":"64","author":"Takemoto","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/kisup.2011.30_bb0085","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/01.ASN.0000120389.09938.21","article-title":"Kidney-specific inactivation of the megalin gene impairs trafficking of renal inorganic sodium phosphate cotransporter (NaPi-IIa)","volume":"15","author":"Bachmann","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/kisup.2011.30_bb0090","first-page":"F746","article-title":"Kinetics of monocyte 1 alpha-hydroxylase in renal failure","volume":"268","author":"Gallieni","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1038\/kisup.2011.30_bb0095","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1210\/jc.2004-0360","article-title":"Vitamin D2 is much less effective than vitamin D3 in humans","volume":"89","author":"Armas","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/kisup.2011.30_bb0100","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1210\/jc.2007-2308","article-title":"Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D","volume":"93","author":"Holick","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/kisup.2011.30_bb0105","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/ajcn\/87.6.1738","article-title":"25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions","volume":"87","author":"Heaney","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.1038\/kisup.2011.30_bb0110","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1210\/jcem-59-6-1063","article-title":"Plasma vitamin D metabolite concentrations in chronic renal failure: effect of oral administration of 25-hydroxyvitamin D3","volume":"59","author":"Halloran","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/kisup.2011.30_bb0115","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/ki.1988.190","article-title":"Extra-renal production of calcitriol in chronic renal failure","volume":"34","author":"Dusso","year":"1988","journal-title":"Kidney Int"},{"key":"10.1038\/kisup.2011.30_bb0120","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1359\/jbmr.080607","article-title":"Vitamin D metabolites and calcium absorption in severe vitamin D deficiency","volume":"23","author":"Need","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1038\/kisup.2011.30_bb0125","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/archinte.168.15.1629","article-title":"25-hydroxyvitamin D levels and the risk of mortality in the general population","volume":"168","author":"Melamed","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1038\/kisup.2011.30_bb0130","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ki.2008.549","article-title":"Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients","volume":"75","author":"Courbebaisse","year":"2009","journal-title":"Kidney Int"},{"key":"10.1038\/kisup.2011.30_bb0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.ajkd.2007.04.010","article-title":"Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD","volume":"50","author":"Al-Aly","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/kisup.2011.30_bb0140","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1089\/dna.1998.17.551","article-title":"Characterization of the human Megalin\/LRP-2 promoter in vitro and in primary parathyroid cells","volume":"17","author":"Knutson","year":"1998","journal-title":"DNA Cell Biol"},{"key":"10.1038\/kisup.2011.30_bb0145","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2215\/CJN.07131009","article-title":"A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease","volume":"5","author":"Moe","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1\u20132","key":"10.1038\/kisup.2011.30_bb0150","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jsbmb.2010.03.064","article-title":"Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality","volume":"121","author":"Dusso","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1038\/kisup.2011.30_bb0155","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"10.1038\/kisup.2011.30_bb0160","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/nm1275","article-title":"Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach","volume":"11","author":"Lautrette","year":"2005","journal-title":"Nat Med"},{"key":"10.1038\/kisup.2011.30_bb0165","doi-asserted-by":"crossref","first-page":"F781","DOI":"10.1152\/ajprenal.90610.2008","article-title":"ADAM17 upregulation in human renal disease: A role in modulating TGF-\u03b1 availability?","volume":"297","author":"Melenhorst","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/kisup.2011.30_bb0170","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.trsl.2007.12.005","article-title":"Arterial calcification: a tumor necrosis factor-alpha mediated vascular Wnt-opathy","volume":"151","author":"Al-Aly","year":"2008","journal-title":"Transl Res"},{"key":"10.1038\/kisup.2011.30_bb0175","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00109-008-0375-6","article-title":"Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE\/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study","volume":"86","author":"Morange","year":"2008","journal-title":"J Mol Med"},{"key":"10.1038\/kisup.2011.30_bb0180","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1097\/TP.0b013e3181903d25","article-title":"Circulating markers of endothelial dysfunction interact with proteinuria in predicting mortality in renal transplant recipients","volume":"86","author":"van Ree","year":"2008","journal-title":"Transplantation"},{"key":"10.1038\/kisup.2011.30_bb0185","first-page":"152A","article-title":"Inhibition of monocyte ADAM17 by paricalcitol may provide renal and cardiovascular protection in human kidney disease","volume":"21","author":"Dusso","year":"2010","journal-title":"J Am Soc Nephrol"}],"container-title":["Kidney International Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171615310297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171615310297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T17:10:14Z","timestamp":1560532214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2157171615310297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S2157171615310297"],"URL":"https:\/\/doi.org\/10.1038\/kisup.2011.30","relation":{},"ISSN":["2157-1716"],"issn-type":[{"value":"2157-1716","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}